Results 51 to 60 of about 16,838,925 (259)

Implementing Health‐Related Quality of Life Assessment in Pediatric Oncology: A Feasibility Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background There is growing interest in embedding health‐related quality of life (HRQoL) assessment and patient‐reported outcome measures (PROMs) within clinical cancer care. This study evaluated the feasibility, acceptability, and usability of implementing an electronic PROM (ePROM) platform to measure HRQoL in children with cancer ...
Mikaela Doig   +13 more
wiley   +1 more source

Treatment Decision‐Making Roles and Preferences Among Adolescents and Young Adults With Cancer

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Decision‐making (DM) dynamics between adolescents and young adults (AYAs) with cancer, parents, and oncologists remain underexplored in diverse populations. We examined cancer treatment DM preferences among an ethnically and socioeconomically diverse group of AYAs and their parents.
Amanda M. Gutierrez   +14 more
wiley   +1 more source

Influence of vitamin D on biomechanical microstructure and properties of patients with hip fracture. [PDF]

open access: yes, 2017
Valorar niveles séricos de 25-hidroxivitamina D -25(OH)D-, hormonas con influencia sobre el metabolismo óseo (parathormona -PTH- y factor de crecimiento insulínico -IGF-I-), marcadores de remodelado óseo (MRO) (telopéptido carboxilo-terminal del colágeno
(Coordinador)   +4 more
core  

Solar cycles: the past evolution influence [PDF]

open access: yes, 2009
The so-called solar cycle is generally characterized by the quasi-periodic oscillatory evolution of the photospheric spots number. This quasi-periodic pattern has always been an intriguing question.
Alexis Klutsch   +4 more
core   +1 more source

Parent Quality of Life at Two Years Following Their Child's Completion of Acute Lymphoblastic Leukemia Treatment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Parents of children treated for acute lymphoblastic leukemia (ALL) often experience significant caregiver burden and disruption to their well‐being. While parent quality of life (QoL) during treatment is well characterized, little is known about outcomes during early survivorship.
Sara Dal Pra   +3 more
wiley   +1 more source

Veil of influence: the legacy of John Rawls [PDF]

open access: yes, 2003
Michael Saward looks at the influence of the work of John ...
Saward, Michael
core   +2 more sources

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano   +7 more
wiley   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm   +10 more
wiley   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost   +10 more
wiley   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy